drugset / Trial / NCT00110487

Study Evaluating ERB-041 in Endometriosis in Reproductive-Age Women

NCT00110487 ↗

Phase 2 Completed 200 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of this investigational study is to determine if a study medication is safe and effective in reducing the symptoms associated with endometriosis; if the study medication reduces the need for pain medication for endometriosis symptoms; and if the study medication improves a participant's ability to carry out daily activities. Qualified participants will receive no cost treatment, which may include study-related examinations, diagnostic procedures including a Pap smear, laboratory testing, and a mammogram (aged 40-45). Qualified participants will also receive study medication at no cost. As a participant, the study volunteer may also experience the satisfaction of knowing she is helping the advancement of women's health care.

Timeline

Start
2005-01
Primary completion
—
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject PRINABEREL Small molecule — —

Indications